Kornimate/medical-research-clean huggingface dataset:
prevalence of tapia's syndrome in weaning unit

Conditions: Tapia's Syndrome

Summary: tapia syndrome is a rare and poorly understood pathology. it is defined by a concomitant attack of the recurrent (branch of x) and hypoglossal (xii) nerves of peripheral or central origin. it is characterized by the paralysis of a vocal cord and the ipsilateral half of tongue. this damage is most often unilateral but it can also be bilateral. it results in dysphonia and swallowing disorders. tapia syndrome is a rare and poorly understood pathology. to date, less than 100 cases have been described in the literature. previous works are mainly case reports and literature reviews. no prevalence study has been performed to date. furthermore, disagreements persist regarding the semiology. indeed, the involvement of the soft palate is not always described.

the main aim of this study was to determine the prevalence of tapia syndrome in patients admitted to weaning unit after prolonged (\>48h) orotracheal intubation in the icu. the secondary objectives are to: * describe the clinical semiology of tapia syndrome : lingual involvement, soft palate involvement, impairment of phonation and swallowing ; * describe the paraclinical features of tapia syndrome: recurrent involvement, laryngeal and lingual involvement; * identify factors associated with tapia's syndrome

Eligibility criteria:
inclusion criteria: * hospitalized in weaning unit * duration of orotracheal intubation in the icu greater than 48 hours; * glasgow score greater than or equal to 13 ; * patient at least 18 years of age at the time of inclusion; * affiliation with a social security system or beneficiary of such a system ; * oral, free, informed and express consent of the patient. exclusion criteria: * known history of ent or neurological pathologies (stroke, head trauma, neurodegenerative disease, brain tumor, ent cancer); * known tumors in the vicinity of the x-nerve pathway; * ortner's syndrome (left recurrent nerve compression through the left atrium in mitral stenosis); * left lung cancer with subaortic lesion; * history of cervical adenopathy compressing the x nerve; * presence of a cervical or cerebral abscess; * 24-hour ventilated patient; * refusal of the patient or designated trusted person to participate in the study; * person subject to a safeguard of justice measure ;
the safe-line technique as additional attempt to mitigate spinal cord ischemia after endovascular exclusion of taaa

Conditions: Thoracoabdominal Aortic Aneurysm

Summary: to assess safety and feasebility of the "safe-line" technique in a multicenter international collaboration.

to assess safety and efficacy of a technique for temporary aneurysm sac re-perfusion (tasrep) after total endovascular exclusion of taaa, using a guide-wire left into the aneurysm sac. the technique can be applied both in elective that urgent cases. the guide-wire aim to be a "safe-line" for fast temporary trans-sealing aneurysm sac re-perfusion in case of sci occurring in the early post-operative period (48-to 72h). before completing exclusion, from the percutaneous femoral access, a second buddy-wire (v-18 guidewire; boston scientific) is advanced and left posterior to the endograft into the aneurysmal sac; through the main guide-wire, the final aneurysm exclusion is completed with distal stent-graft deployment and the femoral access sealed with proglide leaving in place the sole v.018 draped in a sterile fashion. in the case of sci occurrence in the post-operative period up to 48-72 hrs, the trans-sealing v.18 "safe-line" can be rapidly exchanged with a 6f/65 cm long destination cm guiding sheath (terumo) and positioned into the aneurysmal sac; this can be connected to a 6f introducer from the contralateral femoral artery and the sac perfused in a retrograde fashion.

Eligibility criteria:
inclusion criteria: * thoraco-abdominal aortic aneurysm including type i,ii,iii,iv and v. * pararenale aneurysm * thoracoabdominal aortic aneurysm elective and urgent, endovascular repair; * endovascular repair of any thoracoabdominal aortic condition exclusion criteria: -thoraco-abdominal aortic aneurysm open repair
study of daptomycin in subjects undergoing surgery for osteomyelitis associated with an infected prosthetic caused by staphylococci

Conditions: Osteomyelitis

Summary: this is a research study designed to look at the efficacy and safety of daptomycin given at a dose of 6 mg/kg or 8 mg/kg in subjects being treated for prosthetic hip or knee infections caused by staphylococci. these types of bacteria are among the most common types of bacteria causing infections of prosthetic joints.


Eligibility criteria:
inclusion criteria: * subject must be between the ages of 18 and 80, inclusive * subject must have a diagnosis of prosthetic joint infection (pji) in a hip or knee joint which has never previously been totally revised because of an infection and for which they are anticipated to undergo a two-stage replacement surgery * subject must have a positive microbiological identifier of staphylococci. * if subject is female of childbearing potential, must be willing to practice reliable birth control exclusion criteria: * subject has permanent intravascular prosthetic material such as heart valves or pacemakers * subject has a creatinine clearance (clcr) \<30 ml/min as determined by the cockcroft-gault equation using actual body weight. * subject has significant hepatic dysfunction * subject has a fungal or mycobacterial pji * subject is known to be hiv-infected with cd4 count ≤ 200 cells/ mm3 * subject has an abnormal creatine phosphokinase (cpk) (elevated cpk level ≥ 2x uln) at baseline as measured by central laboratory * subject is currently under treatment with chemotherapeutic agents excluding chronic maintenance therapy (e.g. tamoxifen to prevent relapse of primary breast cancer) * subject is pregnant, nursing, or lactating. * subject is receiving or is expected to receive chronic immunosuppressive therapy during the study.

Keywords: osteomyelitis prosthetic hip prosthetic knee mrsa osteomyelitis associated with an infected prosthetic hip or knee joint staphylococci
impact of time restricted feeding on daily protein requirements

Conditions: Nutrition Disorders in Old Age

Summary: the investigators aim to assess 24-hour protein kinetics at two different levels of protein intake: 0.8 (rda) and 1.6g/kg/day (2rda) during a normal dietary (trad) and a time restricted feeding (trf) pattern in older adults.

the investigators aim to assess 24-hour protein kinetics at two different levels of protein intake: 0.8 (rda) and 1.6g/kg/day (2rda) during a normal dietary (trad) and a time restricted feeding (trf) pattern in older adults. individuals in the trf pattern will only consume food during a 6-hour eating period and fast for the remaining 18 hours. individuals in the trad pattern will consume isocaloric and isonitrogenous (rda or 2rda) diet but consume an all-beef-breakfast. participants will consume oral stable isotopes to measure muscle protein synthesis (mps), whole-body muscle protein breakdown (mpb), and whole-body protein balance (wbpb). appropriate muscle, blood samples, and urine will be collected throughout a 24-hour metabolic trial following a 2-day controlled diet.

Eligibility criteria:
inclusion criteria: 1. men and women ages 50-75 years. 2. bmi 20-30 kg/m2 inclusive. 3. capable of providing informed consent. 4. covid-19 negative and/or asymptomatic exclusion criteria: 1. subject who does not/will not eat animal protein sources. 2. body mass index \ 30. 3. hemoglobin \<10g/dl at screening. 4. platelets \<150,000/ul at screening. 5. history of diabetes. 6. history of chemotherapy or radiation therapy for cancer in the 6 months prior to enrollment. 7. history of gastrointestinal bypass/reduction surgery. 8. history of a chronic inflammatory disease (e.g. what?) 9. currently receiving androgen (e.g., testosterone) or anabolic (e.g., gh, igf-i) therapy. 10. currently using prescription blood thinning medications. 11. currently using corticosteroid medications. 12. unable or unwilling to suspend aspirin use for 7 days prior to visit 3. 13. unwilling to avoid using protein or amino-acid supplements during participation. 14. subjects who are unwilling to fast overnight. 15. participating in \>200 minutes/week of vigorous exercise and/or \>4 days/week of resistance training.
impact of perioperative anesthetic management on renal cancer progression.

Conditions: Perioperative Anesthetic; Renal Cancer

Summary: the relationship between perioperative drugs, including preoperative medications, anesthetics, and analgesics, and postoperative outcomes in cancer patients is a complex and evolving field of study. understanding how those medications might impact outcomes such as pain, acute kidney injury, and recurrence is crucial for optimizing perioperative care in renal cancer patients.

this retrospective study will investigate the association of perioperative drugs on short and long-term postoperative outcomes in patients undergoing kidney surgeries for renal cell carcinoma.

Eligibility criteria:
inclusion criteria: 1. adult participants (18 years of age or older) 2. participants having radical or partial nephrectomies with curative intent. exclusion criteria: 1. patients with distant metastatic disease and those with multiple (more than 1) primary tumors at the time of the nephrectomy 2. biopsies 3. participants who had radiofrequency or microwave ablations.
sirt1 gene polymorphism with premature myocardial infarction in young egyptian patients

Conditions: Premature Myocardial Infarction in Young Egyptian Patients

Summary: this is an observertional study aimed at study the association of sirt1(rs7069102 ) gene polymorphism with premature myocardial infarction in young egyptian patients


Eligibility criteria:
inclusion criteria: * all patient with recent mi admitted to sohag university hospital , ccu under 40 years exclusion criteria: * patients above 40 year old. * patients with malignancies, major trauma or surgery in the previous six months, and acute or chronic infectious disease
study of the effects of the pulsed-dye laser at 585nm and 595nm to treat post-operative scars on suture-removal day

Conditions: Cicatrix; Scars

Summary: the purpose of this study is to compare the effects of the pulsed-dye laser (pdl) at two different wavelengths, 585nm and 595nm, in the treatment of post-surgical scars starting on suture-removal day.

many treatment modalities have been used for the treatment of scars such as dermabrasion, cryotherapy, intralesional corticosteroids, surgical scar revision, and lasers, among others. previous studies have shown that treatment of scars with the pulsed dye laser (pdl) alone or in combination with other modalities (e.g. corticosteroids, 5-fluoruracil, silicone sheets) improves the vascularity, pliability, color, and height of hypertrophic scars and keloids. currently, the pdl has become the laser of choice for the treatment of scars. to our knowledge, there are no reports in the literature comparing the effects of different wavelengths of the pdl for the treatment of scars. the objective of this study was to compare the effects of the pdl at 585nm vs 595nm in the treatment of postsurgical linear scars starting the day of suture removal.

Eligibility criteria:
inclusion criteria: * age 18-65 * postoperative linear scars greater than 6 cm * skin photo-types i-iv exclusion criteria: * patient should not be taking any systemic, topical, or intralesional treatment of the scars

Keywords: pulsed-dye laser
safety and tolerability of ain457 in adults (18-65 years) with psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: this study is designed as an extension study to the proof-of-concept trial cain457a2206 in patients with psoriatic arthritis and aims to provide continuous treatment with ain457 for patients in the core trial, to obtain safety and tolerability information. the study will address the evaluation of efficacy following doses of 3 mg/kg ain457 given every 4 weeks over a period initially up to 6 months (part 1) and based on the risk/benefit balance of ain457 in psoriatic arthritis a decision will be made as to whether or not to continue dosing for another 6 month period (part 2).


Eligibility criteria:
inclusion criteria: * patients who participated and completed the core cain457a2206 study up to and including the end of the study (eos) visit, i.e. visit 16 (week 24), were allowed to enter the extension study upon signing informed consent. * patients who discontinued the core study due to unsatisfactory therapeutic effect at their visit 14 (week 16) or a later visit could enter the extension study within three weeks of completing the study discontinuation visit of the core study, provided that at their discontinuation visit they met the criteria below. patients who did not enter the extension study within 3 weeks of completing the study discontinuation visit of the core study, were to have an additional baseline visit (visit 17) and required to meet the criteria below: * the number of tender joints was the same or more than the core study baseline; or, * the number of swollen joints was the same or more than the core study baseline; or, * there was no improvement compared with the core study baseline in at least three of the following five domains: patient global assessment, physician global assessment, patient pain assessment, health assessment questionnaire and crp exclusion criteria: * patients for whom continued treatment with ain457 is not considered appropriate by the treating physician. * patients who were non-compliant or who demonstrated a major protocol deviation in the core cain457a2206 study. * patients who discontinued from the core cain457a2206 study before visit 14 (week 16), and patients who completed the core study or discontinued the core study more than 2 weeks before the baseline visit. * pregnant or lactating women * presence of active infection * positive ppd or hiv test in patients where repeated testing was deemed appropriate due to their risk profile other protocol-defined inclusion/exclusion criteria may apply

Keywords: psoriatic arthritis igg1k monoclonal antibody interleukin -17a neutralizing
the effect of imb model-based diabetes education and motivational interviewing on care outcomes in adults with t2dm

Conditions: Type2 Diabetes; Self Efficacy; Self Management; HbA1c; BMI

Summary: this study was conducted to examine the effects of imb model-based diabetes education and motivational interviewing for adults with type 2 diabetes on care outcomes this study was conducted to examine the effects of imb model-based diabetes education and motivational interviewing interventions on care outcomes for adults with type 2 diabetes (diabetes knowledge, health belief, self-efficacy, self-management, hba1c and bki̇).

this study was conducted to examine the effects of information, motivation and behavioral skills (imb) model-based diabetes education and motivational interviewing on care outcomes in adults with type 2 diabetes. the study is a single-blind, randomized controlled trial with pre-test, post-test and follow-up test measurements from experimental research designs. the study was carried out in the endocrinology and metabolic diseases polyclinic, and the data were collected between june 2021 and february 2022. the sample of the study (intervention group=30, control group=30) consisted of 60 individuals with type 2 diabetes. study data were collected with adult diabetes information scale, health belief model scale, diabetes self-efficacy scale, diabetes self-management scale and metabolic control parameters follow-up form. imb model-based diabetes education and motivational interview program were applied to the individuals in the experimental group for three months. initially, diabetes education was given in small groups in four sessions, then motivational interviews were held individually every two weeks for a total of five sessions via whatsapp.

Eligibility criteria:
inclusion criteria: * those between the ages of 30-64 * receiving insulin therapy * bmi value of 25 and above * hba1c of 7 and above * at least primary school graduate and can speak turkish * no communication barrier (speech, vision or hearing problem) * having a smart phone and internet access * individuals who agree to participate in the research. exclusion criteria: * those who have retinopathy at a level that may hinder the sense of sight. * those with neuropathy at a level that prevents them from doing their daily physical activities * diagnosed with kidney failure * using an insulin pump * pregnant * those with a diagnosis of cancer
pheno- & genotyping pof (who iii)

Conditions: Premature Ovarian Failure (POF); Incipient Ovarian Failure; Poor Response After Ovarian Hyperstimulation; Early Menopause; Hypergonadotropic Amenorrhea

Summary: this study focuses on the phenotyping and genotyping of women with hypergonadotropic ovarian dysfunction (who iii status).

first goal of the study is to phenotype patiens with hypergonadotropic ovarian dysfunction (who iii) adequately. this group includes women with premature ovarian failure (pof), incipient ovarian failure (iof), poor response after ovarian hyperstimulation, early menopause and hypergonadotropic primary amenorrhea. the standardized phenotyping consists of a questionnaire focusing on reproductive, medical, and family history; ultrasonography to assess ovarian reserve and/or antral follicle count and obtaining an extra blood sampling during routine endocrine screening for genotyping. phenotyping of patients presenting with ovarian dysfunction is of crucial importance when genotyping will be performed. the goal of this genotyping will be the identification of genetic factors associated with the (premature) depletion of the stock of ovarian follicles. it will be performed for isolated who iii patients in an association (case-control) study for known candidate genes. in familial who iii cases, genome wide linkage analysis will be performed.

Eligibility criteria:
inclusion criteria: * pof; defined as secondary amenorrhea before 40 years of age and basal fsh \> 40 iu/l * incipient ovarian failure; defined as normo-ovulatory cycles, raised basal fsh \> 12 iu/l * poor response patients; defined as less than 4 oocytes retrieved or cancellation in case of absent follicle growth after ovarian hyperstimulation with 300 iu gonadotropins or cancellation in case of absent follicle growth * women with early menopause (between 40-45 years) * hypergonadotropic primary amenorrhea exclusion criteria: * primary amenorrhea with early development disorders causing absence of ovaries and swyer syndrome (xy)

Keywords: pof iof poor response early menopause primary amenorrhea
comparison of platelet rich fibrin as graft & membrane vs hyaluronic acid & amniotic membrane in the treatment of interradicular defects

Conditions: Furcation Defects

Summary: this study is intended to compare the efficacy of platelet-rich fibrin as a graft and a membrane versus hyaluronic acid(gengigel) and amniotic membrane in the treatment of mandibular grade ii furcation defects.

platelet-rich fibrin is a fraction of plasma that provides a rich source of growth factors and may enhance the stabilization and revascularization of the flaps and grafts. hyaluronic acid is a naturally occurring non-sulfated high molecular weight glycosaminoglycan that forms a critical component of the extracellular matrix and contributes significantly to tissue hydrodynamics, cell migration and proliferation. hence its administration to periodontal wound sites could achieve beneficial effects in periodontal tissue regeneration. amniotic membrane is being used for various regenerative procedures as it is a rich source of various collagen and non-collagen proteins such as laminin, fibronectin and proteoglycan.

Eligibility criteria:
inclusion criteria: * grade ii furcation involvement exclusion criteria: * smokers, * pregnant and lactating women, * systemically compromised patients
novel mhealth physical activity intervention for youth with type 1 diabetes mellitus

Conditions: Type 1 Diabetes

Summary: the goal of this longitudinal cohort study is to learn about a mhealth intervention in type 1 diabetes (t1d) the main question\[s\] it aims to answer are: * does the intervention increase the amount of text messages between the mhealth software and participants? * do the text messages from the nudge software increase moderate to vigorous physical activity (mvpa) in participants? * does the mvpa encouraged by the nudge software improve the hba1c levels of participants? participants will: * receive text messages from the nudge software * report physical activity goals via the text messages to the nudge software * wear both an accelerometer and an actigraph for three weeks (spread out across the beginning, 30 days, and 90 days of participation) * complete surveys at the beginning of participation * complete daily surveys while wearing the devices * complete surveys at the end of participation * record physical activity in study surveys


Eligibility criteria:
inclusion criteria: * participants 12.00-21.99 years old * participants with a physician confirmed t1d diagnosis. * t1d diagnosis was at least 6 months prior to study enrollment * participants are on an intensive insulin regiment (either with an insulin pump or multiple daily injection) * participants must be using a continuous glucose monitor (cgm) * participants and parents/legally authorized representatives (lars) of participants less than 18.00 speak/read english. exclusion criteria: * participants with evidence of type 2 or monogenic diabetes. * participants with a comorbid chronic condition (e.g., renal disease). * participants with presence of severe psychiatric disorders. * participants with a diagnosis of low vision (vision that cannot be corrected with contact lenses or eyeglasses). * participants with limited mobility that would prevent participant from engaging in daily physical activity, self-assessed by participant.
resting energy expenditure using a handheld calorimeter

Conditions: Obesity

Summary: high prevalence of obesity in children has increased associated complications such as type 2 diabetes, hypertension and fatty liver disease. dietitians develop a meal plan that restricts caloric intake by estimating the resting and total daily energy expenditures.estimation of energy needs is most commonly done using predictive equations. reliable and valid energy requirements can be obtained using a traditional metabolic system, however this is an expensive option. handheld indirect calorimeters may be a good alternative to measure energy needs. several studies have been conducted to determine the validity and accuracy of handheld calorimeters in adults and health children, however, to the best of our knowledge, there are no such studies in the overweight and obese pediatric population. the purpose of this study is to validate a handheld indirect calorimeter against a traditional metabolic system in overweight and obese children. if handheld calorimeters can accurately measure resting energy expenditure in overweight and obese adolescents, dietitians will have an opportunity to tailor pediatric weight management interventions based on parameters that are unique to each individual.


Eligibility criteria:
inclusion criteria: * 13-18y of age * bmi 85th percentile or more * no severe illness, neurological and development issues * not on insulin * able to fast overnight exclusion criteria: * not 13-18y of age * bmi under 85th percentile * ill or have neurological and development issues * on insulin

Keywords: resting energy expenditure handheld calorimeter obese and overweight pediatrics